易明医药上半年扣非净利翻番，女副总高瑛去年薪酬高于总经理

Core Insights - Yiming Pharmaceutical (SZ002826) reported a decline in both revenue and net profit for the first half of 2025, with revenue at 311.45 million yuan, down 11.52% year-on-year, and net profit attributable to shareholders at 37.56 million yuan, down 5.27% year-on-year [1][2]. Financial Performance - Revenue for the reporting period was 311,445,583.30 yuan compared to 351,984,809.03 yuan in the same period last year, reflecting an 11.52% decrease [2]. - Net profit attributable to shareholders was 37,557,144.18 yuan, down from 39,646,165.15 yuan, marking a 5.27% decline [2]. - Net profit after deducting non-recurring gains and losses was 25,022,156.54 yuan, which represents a significant increase of 102.33% from 12,366,829.01 yuan in the previous year [1][2]. - The net cash flow from operating activities was 62,458,414.18 yuan, an increase from 46,131,657.93 yuan year-on-year [2]. - Basic and diluted earnings per share were both 0.20 yuan, down from 0.21 yuan [2]. - The weighted average return on equity was 4.96%, slightly down from 5.30% [2]. Asset and Equity Position - Total assets at the end of the reporting period were 1,005,255,294.07 yuan, up from 926,469,234.87 yuan at the end of the previous year [2]. - Net assets attributable to shareholders were 764,048,582.94 yuan, an increase from 739,003,677.36 yuan [2]. Executive Compensation - The vice president of Yiming Pharmaceutical, Gao Ying, received a salary of 701,500 yuan, which is higher than the chairman's salary of 681,600 yuan and the general manager's salary of 614,300 yuan [1][2].